Inventor
XU SHUICHAN
US26 patents
⚠️ This page may combine multiple inventors who share the name “XU SHUICHAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SIGNAL PHARM LLC
17 patentsUS9512124B2Dec 6, 2016
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC32 citations96
US9737541B2Aug 22, 2017
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC12 citations91
US9505764B2Nov 29, 2016
Treatment of cancer with dihydropyrazino-pyrazines
SIGNAL PHARM LLC11 citations83
US9493466B2Nov 15, 2016
Treatment of cancer with TOR kinase inhibitors
SIGNAL PHARM LLC7 citations83
US9375443B2Jun 28, 2016
Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinib
SIGNAL PHARM LLC12 citations83
US9155736B2Oct 13, 2015
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
SIGNAL PHARM LLC16 citations82
US10940152B2Mar 9, 2021
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC1 citations72
US10646493B2May 12, 2020
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC1 citations72
US10004735B2Jun 26, 2018
Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
SIGNAL PHARM LLC4 citations71
US9737535B2Aug 22, 2017
Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
SIGNAL PHARM LLC5 citations71
US11166950B2Nov 9, 2021
Treatment of cancer with TOR kinase inhibitors
SIGNAL PHARM LLC0 citations62
US9937170B2Apr 10, 2018
Treatment of cancer with TOR kinase inhibitors
SIGNAL PHARM LLC1 citations62
US11590139B2Feb 28, 2023
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC0 citations61
US9980963B2May 29, 2018
Treatment of cancer with dihydropyrazino-pyrazines
SIGNAL PHARM LLC0 citations51
US9557338B2Jan 31, 2017
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for tor kinase inhibitory activity
SIGNAL PHARM LLC1 citations50
US10576085B2Mar 3, 2020
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC0 citations37
US9623028B2Apr 18, 2017
Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
SIGNAL PHARM LLC0 citations33
CELGENE CORP
5 patentsUS11149007B2Oct 19, 2021
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP14 citations84
US11325889B2May 10, 2022
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP11 citations83
US11873283B2Jan 16, 2024
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP2 citations71
US11331380B2May 17, 2022
Cereblon-based heterodimerizable chimeric antigen receptors
CELGENE CORP0 citations62
US12404241B2Sep 2, 2025
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP0 citations61
SIGNAL PHARMACEUTICAL LLC
3 patentsUS9428509B2Aug 30, 2016
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARMACEUTICAL LLC6 citations81
US9346812B2May 24, 2016
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARMACEUTICAL LLC6 citations81
US9795607B2Oct 24, 2017
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARMACEUTICAL LLC0 citations49